While the probability of a directly isolated natural product
(e.g., adriamycin or taxanes in the anti-tumor area) being
the actual drug used for the treatment of a given disease in
the future is relatively low, these natural molecules can serve
as lead compounds for the development of analogues,
generated by combinatorial biosynthesis and/or combinatorial
chemistry, with optimized pharmacological properties. Recent
advances in synthetic methodology and strategy are
surmounting the barriers presented by the structural complexity
of most natural products. In addition, natural products
to enable large-scale production of natural products in the
native or engineered organisms have been evolutionarily selected to bind to biological
macromolecules and, thus, represent “privileged structures”,129
which are excellent templates for the synthesis of
novel, biologically active, natural product-like molecules. Of
course, suitable biological assays for evaluation of the
structure-activity relationships (SARs) of the optimization
products are required for all these approaches, and thus, a
truly multidisciplinary, collaborative approach is required for
effective natural product-based drug discovery and developmen
While the probability of a directly isolated natural product(e.g., adriamycin or taxanes in the anti-tumor area) beingthe actual drug used for the treatment of a given disease inthe future is relatively low, these natural molecules can serveas lead compounds for the development of analogues,generated by combinatorial biosynthesis and/or combinatorialchemistry, with optimized pharmacological properties. Recentadvances in synthetic methodology and strategy aresurmounting the barriers presented by the structural complexityof most natural products. In addition, natural productsto enable large-scale production of natural products in thenative or engineered organisms have been evolutionarily selected to bind to biologicalmacromolecules and, thus, represent “privileged structures”,129which are excellent templates for the synthesis ofnovel, biologically active, natural product-like molecules. Ofcourse, suitable biological assays for evaluation of thestructure-activity relationships (SARs) of the optimizationproducts are required for all these approaches, and thus, atruly multidisciplinary, collaborative approach is required foreffective natural product-based drug discovery and developmen
การแปล กรุณารอสักครู่..
While the probability of a directly isolated natural product
(e.g., adriamycin or taxanes in the anti-tumor area) being
the actual drug used for the treatment of a given disease in
the future is relatively low, these natural molecules can serve
as lead compounds for the development of analogues,
generated by combinatorial biosynthesis and/or combinatorial
chemistry, with optimized pharmacological properties. Recent
advances in synthetic methodology and strategy are
surmounting the barriers presented by the structural complexity
of most natural products. In addition, natural products
to enable large-scale production of natural products in the
native or engineered organisms have been evolutionarily selected to bind to biological
macromolecules and, thus, represent “privileged structures”,129
which are excellent templates for the synthesis of
novel, biologically active, natural product-like molecules. Of
course, suitable biological assays for evaluation of the
structure-activity relationships (SARs) of the optimization
products are required for all these approaches, and thus, a
truly multidisciplinary, collaborative approach is required for
effective natural product-based drug discovery and developmen
การแปล กรุณารอสักครู่..